Georgios Meristoudis, Ioannis Ilias, Vasilios Giannakopoulos
A cold vertebral defect is an uncommon finding, especially in Gallium-67-citrate ([67Ga]Ga-citrate) - and [18F]fluorodeoxyglucose ([18F]FDG) - avid lymphomas, representing a diagnostic challenge. Here, we present the case of a patient with non-Hodgkin lymphoma (NHL), in whom the [67Ga]Ga-citrate and [18F]FDG scans showed a diffuse skeletal uptake pattern with concomitant appearance of a cold vertebral defect. Awareness of the different causes of such uptake patterns and accurate clinical information is important to avoid misinterpretation of nuclear studies in oncologic patients.
冷椎体缺损是一种罕见的发现,特别是在67-柠檬酸镓([67Ga] ga -柠檬酸镓)和[18F]氟脱氧葡萄糖([18F]FDG)淋巴瘤中,这是一种诊断挑战。在此,我们报告了一例非霍奇金淋巴瘤(NHL)患者,其[67Ga]枸橼酸镓和[18F]FDG扫描显示弥漫性骨骼摄取模式,并伴有椎体冷缺陷。了解这种摄取模式的不同原因和准确的临床信息对于避免对肿瘤患者核研究的误解很重要。
{"title":"Vertebral photopenia on [67Ga]Ga-citrate and [18F]FDG PET/CT imaging in a patient with non-Hodgkin lymphoma.","authors":"Georgios Meristoudis, Ioannis Ilias, Vasilios Giannakopoulos","doi":"10.5603/NMR.a2022.0042","DOIUrl":"https://doi.org/10.5603/NMR.a2022.0042","url":null,"abstract":"<p><p>A cold vertebral defect is an uncommon finding, especially in Gallium-67-citrate ([67Ga]Ga-citrate) - and [18F]fluorodeoxyglucose ([18F]FDG) - avid lymphomas, representing a diagnostic challenge. Here, we present the case of a patient with non-Hodgkin lymphoma (NHL), in whom the [67Ga]Ga-citrate and [18F]FDG scans showed a diffuse skeletal uptake pattern with concomitant appearance of a cold vertebral defect. Awareness of the different causes of such uptake patterns and accurate clinical information is important to avoid misinterpretation of nuclear studies in oncologic patients.</p>","PeriodicalId":44718,"journal":{"name":"NUCLEAR MEDICINE REVIEW","volume":"26 0","pages":"38-39"},"PeriodicalIF":0.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10801902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: A challenge for modern medicine is the development of clinical protocols for precise diagnosis and therapy. This study aimed to propose a simple method for modification of 2-[18F]FDG used routinely in hospitals in a way, appropriate for patients' personalized radiopharmaceuticals approach.
Material and methods: For the purposes of the presented study chemo selective method for indirect radiofluorination was applauded to custom synthesized aminooxy- and hydrazine-functionalized tetrazines for 18F-glycolation via oxime or hydrazone formation. 2-[18F]FDG produced with medical baby cyclotron in Nuclear Medicine Clinic at the University Hospital St. Marina-Varna, was used. Thin layer chromatography (TLC) and radio TLC were used to follow the progress of synthesis and to determine radio chemical yield (RCY).
Results: The 2-[18F]FDG was modified with two bifunctional tetrazines aminooxy-acetic acid-6-(2-aminooxy-acetoxy)-[1,2,4,5] tetrazin-3-yl ester (Tz1) and {3-[4-(6-phenyl-[1,2,4,5]tetrazin-3-yl)-phenoxy]-propyl}-hydrazine (Tz2) via oxime and hydrazone formation. The radiolabeling was carried out as one-pot reaction with following parameters: temperature 70-75°C; catalyst p- diaminobenzene (Cat.); pH = 4.2; time 30 minutes; RCY = 70-99%. The radiolabeled tetrazines are appropriate for further bioorthogonal (pretargeting) strategy by click reactions with trans-cyclooctene conjugated bioactive molecules. The methodology is applicable to standard clinical conditions.
{"title":"An approach to develop personalized radiopharmaceuticals by modifying 2-[18F]fluoro-2-deoxy-D-glucose (2-[18F]FDG).","authors":"Gergana Simeonova, Boyan Todorov","doi":"10.5603/nmr.93869","DOIUrl":"https://doi.org/10.5603/nmr.93869","url":null,"abstract":"<p><strong>Background: </strong>A challenge for modern medicine is the development of clinical protocols for precise diagnosis and therapy. This study aimed to propose a simple method for modification of 2-[18F]FDG used routinely in hospitals in a way, appropriate for patients' personalized radiopharmaceuticals approach.</p><p><strong>Material and methods: </strong>For the purposes of the presented study chemo selective method for indirect radiofluorination was applauded to custom synthesized aminooxy- and hydrazine-functionalized tetrazines for 18F-glycolation via oxime or hydrazone formation. 2-[18F]FDG produced with medical baby cyclotron in Nuclear Medicine Clinic at the University Hospital St. Marina-Varna, was used. Thin layer chromatography (TLC) and radio TLC were used to follow the progress of synthesis and to determine radio chemical yield (RCY).</p><p><strong>Results: </strong>The 2-[18F]FDG was modified with two bifunctional tetrazines aminooxy-acetic acid-6-(2-aminooxy-acetoxy)-[1,2,4,5] tetrazin-3-yl ester (Tz1) and {3-[4-(6-phenyl-[1,2,4,5]tetrazin-3-yl)-phenoxy]-propyl}-hydrazine (Tz2) via oxime and hydrazone formation. The radiolabeling was carried out as one-pot reaction with following parameters: temperature 70-75°C; catalyst p- diaminobenzene (Cat.); pH = 4.2; time 30 minutes; RCY = 70-99%. The radiolabeled tetrazines are appropriate for further bioorthogonal (pretargeting) strategy by click reactions with trans-cyclooctene conjugated bioactive molecules. The methodology is applicable to standard clinical conditions.</p>","PeriodicalId":44718,"journal":{"name":"NUCLEAR MEDICINE REVIEW","volume":"26 0","pages":"109-115"},"PeriodicalIF":0.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41165366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Francesco Dondi, M. Gregorelli, D. Albano, F. Bertagna, R. Giubbini
{"title":"123I-ioflupane SPECT in the assessment of Parkinson’s disease in a patient with retinitis pigmentosa","authors":"Francesco Dondi, M. Gregorelli, D. Albano, F. Bertagna, R. Giubbini","doi":"10.5603/nmr.a2022.0040","DOIUrl":"https://doi.org/10.5603/nmr.a2022.0040","url":null,"abstract":"","PeriodicalId":44718,"journal":{"name":"NUCLEAR MEDICINE REVIEW","volume":"1 1","pages":""},"PeriodicalIF":0.9,"publicationDate":"2022-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42306672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Haluk B Sayman, Kubra N Toplutas, James Tunick, Omer Aras
We present the first 99mTc-Vitamin C single-photon emission computed tomography/computed tomography (SPECT/CT) images obtained in patients with SARS-CoV-2 (COVID-19) infection. The CT portion of SPECT/CT images showed mostly peripheral patchy and ground-glass opacities in both lungs, which are consistent with a diagnosis of SARS-CoV-2-associated pneumonia in both patients. 99mTc-Vitamin C SPECT images showed increased tracer uptake corresponding to abnormal lung findings seen on CT in patient 1 who was newly diagnosed and treatment naïve. However, no abnormal uptake corresponding to lung CT findings was seen in patient 2 who received anti-SARS-CoV-2 treatment.
{"title":"99mTc-Vitamin C SPECT/CT imaging in SARS-CoV-2 associated pneumonia.","authors":"Haluk B Sayman, Kubra N Toplutas, James Tunick, Omer Aras","doi":"10.5603/NMR.a2022.0026","DOIUrl":"https://doi.org/10.5603/NMR.a2022.0026","url":null,"abstract":"<p><p>We present the first 99mTc-Vitamin C single-photon emission computed tomography/computed tomography (SPECT/CT) images obtained in patients with SARS-CoV-2 (COVID-19) infection. The CT portion of SPECT/CT images showed mostly peripheral patchy and ground-glass opacities in both lungs, which are consistent with a diagnosis of SARS-CoV-2-associated pneumonia in both patients. 99mTc-Vitamin C SPECT images showed increased tracer uptake corresponding to abnormal lung findings seen on CT in patient 1 who was newly diagnosed and treatment naïve. However, no abnormal uptake corresponding to lung CT findings was seen in patient 2 who received anti-SARS-CoV-2 treatment.</p>","PeriodicalId":44718,"journal":{"name":"NUCLEAR MEDICINE REVIEW","volume":"25 2","pages":"127-128"},"PeriodicalIF":0.9,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9878461/pdf/nihms-1864454.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9626094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: This diagnostic study aimed to assess degree of agreement between dacryoscintigraphy and dacryocystography as supporting examinations in patients with primary acquired nasolacrimal duct obstruction (PANDO). Patients with PANDO who complained of epiphora and visited our outpatient clinic were subsequently sent for dacryoscintigraphy and dacryocystography examinations. Side effects and convenience of both examinations were assessed by observation and questionnaire.
Material and methods: Through irrigation and probing, there were 47 out of 62 eyes were found with PANDO. As much as 87.1% subjects were female, with mostly (74.2%) aged > 40 years old. With dacryoscintigraphy, time needed to reach sac was 0 minutes, 5 minutes (duct), and 12.5 minutes (nasal cavity).
Results: Degree of agreement between both examinations was 83.8% to determine obstruction and 70.9% to locate obstruction. There were 22 subjects complained about pain in dacryocystography examination while none with dacryoscintigraphy (p < 0.005). Sixteen subjects feel dacryoscintigraphy examination was more convenient, eleven subjects feel dacryocystohraphy was more convenient, while 4 subjects feel the two examinations were similar.
Conclusions: Even though dacryocystography examination was considered more painful than dacryoscintigraphy, both examinations had high convenience level for patients. Dacryoscintigraphy and dacryocystography also had a good agreement in detecting and locating obstruction in PANDO.
{"title":"Degree of agreement between dacryoscintigraphy and dacryocystography examinations results in primary acquired nasolacrimal duct obstruction.","authors":"Elyas Aditya, Yunia Irawati, Benny Zulkarnaien, Joedo Prihartono","doi":"10.5603/NMR.a2022.0004","DOIUrl":"https://doi.org/10.5603/NMR.a2022.0004","url":null,"abstract":"<p><strong>Background: </strong>This diagnostic study aimed to assess degree of agreement between dacryoscintigraphy and dacryocystography as supporting examinations in patients with primary acquired nasolacrimal duct obstruction (PANDO). Patients with PANDO who complained of epiphora and visited our outpatient clinic were subsequently sent for dacryoscintigraphy and dacryocystography examinations. Side effects and convenience of both examinations were assessed by observation and questionnaire.</p><p><strong>Material and methods: </strong>Through irrigation and probing, there were 47 out of 62 eyes were found with PANDO. As much as 87.1% subjects were female, with mostly (74.2%) aged > 40 years old. With dacryoscintigraphy, time needed to reach sac was 0 minutes, 5 minutes (duct), and 12.5 minutes (nasal cavity).</p><p><strong>Results: </strong>Degree of agreement between both examinations was 83.8% to determine obstruction and 70.9% to locate obstruction. There were 22 subjects complained about pain in dacryocystography examination while none with dacryoscintigraphy (p < 0.005). Sixteen subjects feel dacryoscintigraphy examination was more convenient, eleven subjects feel dacryocystohraphy was more convenient, while 4 subjects feel the two examinations were similar.</p><p><strong>Conclusions: </strong>Even though dacryocystography examination was considered more painful than dacryoscintigraphy, both examinations had high convenience level for patients. Dacryoscintigraphy and dacryocystography also had a good agreement in detecting and locating obstruction in PANDO.</p>","PeriodicalId":44718,"journal":{"name":"NUCLEAR MEDICINE REVIEW","volume":"25 1","pages":"12-17"},"PeriodicalIF":0.9,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10535483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Omer Aras, Cetin Demirdag, Harikrishna Kommidi, Richard Ting, Haluk B Sayman
Prostate-specific membrane antigen (PSMA) - based radiopharmaceuticals are promising for the evaluation of PSMA-positive non-prostate cancers. In this case study, 18F-BF3-Cy3-ACUPA and 68Ga-PSMA positron emission tomography/magnetic resonance imaging (PET/MRI) were compared in a patient with metastatic colon cancer. Both 18F-BF3-Cy3-ACUPA and 68Ga-PSMA PET/MRI showed biopsy-proven metastatic left external iliac adenopathy, highlighting the feasibility of PSMA uptake in PET/MRI of metastatic nodal disease from colon cancer. Along with imaging evaluation, PSMA-based radiopharmaceuticals may also be used as a surrogate imaging tracer for potential theranostic applications using alpha or beta emitters in the context of PSMA-directed radiopharmaceutical therapy in advanced and progressive colorectal cancer.
{"title":"Radiopharmaceutical for detecting PSMA - positive metastatic colon cancer: Matched-pair comparison of 18F-BF3-Cy3-ACUPA and 68Ga-PSMA PET/MRI.","authors":"Omer Aras, Cetin Demirdag, Harikrishna Kommidi, Richard Ting, Haluk B Sayman","doi":"10.5603/NMR.a2022.0027","DOIUrl":"https://doi.org/10.5603/NMR.a2022.0027","url":null,"abstract":"<p><p>Prostate-specific membrane antigen (PSMA) - based radiopharmaceuticals are promising for the evaluation of PSMA-positive non-prostate cancers. In this case study, 18F-BF3-Cy3-ACUPA and 68Ga-PSMA positron emission tomography/magnetic resonance imaging (PET/MRI) were compared in a patient with metastatic colon cancer. Both 18F-BF3-Cy3-ACUPA and 68Ga-PSMA PET/MRI showed biopsy-proven metastatic left external iliac adenopathy, highlighting the feasibility of PSMA uptake in PET/MRI of metastatic nodal disease from colon cancer. Along with imaging evaluation, PSMA-based radiopharmaceuticals may also be used as a surrogate imaging tracer for potential theranostic applications using alpha or beta emitters in the context of PSMA-directed radiopharmaceutical therapy in advanced and progressive colorectal cancer.</p>","PeriodicalId":44718,"journal":{"name":"NUCLEAR MEDICINE REVIEW","volume":"25 2","pages":"129-130"},"PeriodicalIF":0.9,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9878462/pdf/nihms-1863381.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9626090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
<p><strong>Background: </strong>Prostate-specific membrane antigen (PSMA) is a cell surface glycoprotein with a large extracellular domain with overexpression of the prostatic tumour cells. Several small molecules of PSMA ligands of inhibitors binding to the active site of PSMA were developed. [99mTc]Tc-PSMA-T4 is a new radiopharmaceutical (Polatom) for imaging loco-regional metastases and/or local relapse in patients with prostate cancer. The purpose of this work was to evaluate the clinical application of SPECT-CT imaging with [99mTc]Tc-PSMA-T4 in patients with recurrent prostate cancer.</p><p><strong>Material and methods: </strong>Thirty-six patients with prostate cancer, aged 60-80 years with biochemical relapse of PSA (ranged from 0.1 to 73 ng/mL) were included. Three patients were studied after tru-cut biopsy, hormonal and cytoreductive radiotherapy and 33 patients out of 36 - after radical treatment (total prostatectomy or definitive radiotherapy of the tumour). All of them underwent whole-body imaging examinations with subsequent target SPECT-CT studies of the pelvis, abdomen and/or chest, 1-3 hrs post i.v. administration of [99mTc]Tc-PSMA-T4. The average activity dose was 6.3 MBq/kg in a man of 70 kg. A Dual-head SPECT-CT gamma camera with a low dose CT scan (Symbia T2, Siemens) was used. The images were interpreted based on all other clinical and radiological data. Follow-up could be conducted in 11/36 patients during that period.</p><p><strong>Results: </strong>Normal biodistribution of the radiopharmaceutical with high activity background was observed in the liver, spleen, kidneys, lacrimal and salivary glands, bowels and urinary bladder. Positive imaging for local relapse in the prostate bad was imaged in 21 patients, lymph node metastases - in 16 cases, bone lesions - in 10 cases, pulmonary metastases - in 2 cases, hepatic lesions were visualised in one of them and in another - adrenal suprarenal metastasis with intensive tracer uptake significant for overexpression of PSMA. There was a suspicion for local recurrences in 4 patients with negative MRT studies who were followed up. In 3 cases, previously treated bone metastases were partially negative without tracer uptake, only some progressive bone lesions were positive. Five patients were with negative results. Sensitivity was 84.37% (27/32), specificity - 100% (4/4) and accuracy - 86.11% (31/36).</p><p><strong>Conclusions: </strong>In conclusion SPECT-CT imaging with [99mTc]Tc-PSMA-T4 could be applied in patients with prostate cancer for the diagnosis of recurrent disease to determine personalized treatment for each patient. Specific uptake of this tracer, depicted by SPECT-CT images has clinical importance of identifying and assessing PSMA expression before consideration of Radio Ligand Therapy (RLT) with [¹⁷⁷Lu]Lu-PSMA. SPECT-CT imaging with [99mTc]PSMA is promising and reliable nuclear medicine approach to monitoring therapeutic effect after treatment and for restaging of the di
{"title":"SPECT-CT Imaging with [99mTc]PSMA-T4 in patients with Recurrent Prostate Cancer.","authors":"Sonya Sergieva, Radoslav Mangaldgiev, Milena Dimcheva, Kamen Nedev, Zahary Zahariev, Bozhil Robev","doi":"10.5603/NMR.2021.0018","DOIUrl":"https://doi.org/10.5603/NMR.2021.0018","url":null,"abstract":"<p><strong>Background: </strong>Prostate-specific membrane antigen (PSMA) is a cell surface glycoprotein with a large extracellular domain with overexpression of the prostatic tumour cells. Several small molecules of PSMA ligands of inhibitors binding to the active site of PSMA were developed. [99mTc]Tc-PSMA-T4 is a new radiopharmaceutical (Polatom) for imaging loco-regional metastases and/or local relapse in patients with prostate cancer. The purpose of this work was to evaluate the clinical application of SPECT-CT imaging with [99mTc]Tc-PSMA-T4 in patients with recurrent prostate cancer.</p><p><strong>Material and methods: </strong>Thirty-six patients with prostate cancer, aged 60-80 years with biochemical relapse of PSA (ranged from 0.1 to 73 ng/mL) were included. Three patients were studied after tru-cut biopsy, hormonal and cytoreductive radiotherapy and 33 patients out of 36 - after radical treatment (total prostatectomy or definitive radiotherapy of the tumour). All of them underwent whole-body imaging examinations with subsequent target SPECT-CT studies of the pelvis, abdomen and/or chest, 1-3 hrs post i.v. administration of [99mTc]Tc-PSMA-T4. The average activity dose was 6.3 MBq/kg in a man of 70 kg. A Dual-head SPECT-CT gamma camera with a low dose CT scan (Symbia T2, Siemens) was used. The images were interpreted based on all other clinical and radiological data. Follow-up could be conducted in 11/36 patients during that period.</p><p><strong>Results: </strong>Normal biodistribution of the radiopharmaceutical with high activity background was observed in the liver, spleen, kidneys, lacrimal and salivary glands, bowels and urinary bladder. Positive imaging for local relapse in the prostate bad was imaged in 21 patients, lymph node metastases - in 16 cases, bone lesions - in 10 cases, pulmonary metastases - in 2 cases, hepatic lesions were visualised in one of them and in another - adrenal suprarenal metastasis with intensive tracer uptake significant for overexpression of PSMA. There was a suspicion for local recurrences in 4 patients with negative MRT studies who were followed up. In 3 cases, previously treated bone metastases were partially negative without tracer uptake, only some progressive bone lesions were positive. Five patients were with negative results. Sensitivity was 84.37% (27/32), specificity - 100% (4/4) and accuracy - 86.11% (31/36).</p><p><strong>Conclusions: </strong>In conclusion SPECT-CT imaging with [99mTc]Tc-PSMA-T4 could be applied in patients with prostate cancer for the diagnosis of recurrent disease to determine personalized treatment for each patient. Specific uptake of this tracer, depicted by SPECT-CT images has clinical importance of identifying and assessing PSMA expression before consideration of Radio Ligand Therapy (RLT) with [¹⁷⁷Lu]Lu-PSMA. SPECT-CT imaging with [99mTc]PSMA is promising and reliable nuclear medicine approach to monitoring therapeutic effect after treatment and for restaging of the di","PeriodicalId":44718,"journal":{"name":"NUCLEAR MEDICINE REVIEW","volume":"24 2","pages":"70-81"},"PeriodicalIF":0.9,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39303509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aleksandra Ledwon, Przemysław Soczomski, Ewa Paliczka-Cieslik, Aleksandra Blewąska, Daria Handkiewicz-Junak
The Na+/Isymporter (NIS) is an intrinsic plasma membrane glycoprotein that mediates the active uptake of Iin the thyroid and other tissues such as salivary glands, gastric mucosa and lactating mammary gland. Physiologically, NIS is expressed in the breast exclusively during gestation and lactation. In vitro and in vivo studies confirmed that lactogenic hormones, including prolactin, can induce functional NIS expression in mammary tissue. Hyperprolactinemia is common in patients with end-stage renal disease (ESRD).
{"title":"False-positive radioiodine uptake in breasts in a female haemodialysis patient.","authors":"Aleksandra Ledwon, Przemysław Soczomski, Ewa Paliczka-Cieslik, Aleksandra Blewąska, Daria Handkiewicz-Junak","doi":"10.5603/NMR.2021.0030","DOIUrl":"https://doi.org/10.5603/NMR.2021.0030","url":null,"abstract":"The Na+/Isymporter (NIS) is an intrinsic plasma membrane glycoprotein that mediates the active uptake of Iin the thyroid and other tissues such as salivary glands, gastric mucosa and lactating mammary gland. Physiologically, NIS is expressed in the breast exclusively during gestation and lactation. In vitro and in vivo studies confirmed that lactogenic hormones, including prolactin, can induce functional NIS expression in mammary tissue. Hyperprolactinemia is common in patients with end-stage renal disease (ESRD).","PeriodicalId":44718,"journal":{"name":"NUCLEAR MEDICINE REVIEW","volume":"24 2","pages":"122-123"},"PeriodicalIF":0.9,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39303848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sara Kurkowska, Bożena Birkenfeld, Hanna Piwowarska-Bilska
SPECT/CT imaging is transitioning from solely qualitative applications to quantitative analysis. Quantitative SPECT/CT systems require proper calibration, optimization and quality control. Various types of modern SPECT/CT scanners have different software for calibration and quality control (QC). There is still no standardization in this regard for quantitative SPECT/CT. This issue hinders the exchange of obtained results across centers and stunts the development of repeatable and reproducible measurements. The unification and standardization of calibration and quality control techniques for quantitative SPECT/CT systems is currently a pressing need for nuclear medicine departments. The present study presents three selected physical quantities characterizing the quality of quantitative SPECT/CT system and seven quantities, currently used in the literature, to assess the quality of quantitative SPECT/CT images. The measurement of these parameters requires the use of standard gamma camera software for QC, external programs for quantitative analysis of recorded data and clinical software. The authors hope this will help physicists who are willing to perform quantitative SPECT/CT in their departments.
{"title":"Physical quantities useful for quality control of quantitative SPECT/CT imaging.","authors":"Sara Kurkowska, Bożena Birkenfeld, Hanna Piwowarska-Bilska","doi":"10.5603/NMR.2021.0020","DOIUrl":"https://doi.org/10.5603/NMR.2021.0020","url":null,"abstract":"<p><p>SPECT/CT imaging is transitioning from solely qualitative applications to quantitative analysis. Quantitative SPECT/CT systems require proper calibration, optimization and quality control. Various types of modern SPECT/CT scanners have different software for calibration and quality control (QC). There is still no standardization in this regard for quantitative SPECT/CT. This issue hinders the exchange of obtained results across centers and stunts the development of repeatable and reproducible measurements. The unification and standardization of calibration and quality control techniques for quantitative SPECT/CT systems is currently a pressing need for nuclear medicine departments. The present study presents three selected physical quantities characterizing the quality of quantitative SPECT/CT system and seven quantities, currently used in the literature, to assess the quality of quantitative SPECT/CT images. The measurement of these parameters requires the use of standard gamma camera software for QC, external programs for quantitative analysis of recorded data and clinical software. The authors hope this will help physicists who are willing to perform quantitative SPECT/CT in their departments.</p>","PeriodicalId":44718,"journal":{"name":"NUCLEAR MEDICINE REVIEW","volume":"24 2","pages":"93-98"},"PeriodicalIF":0.9,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39303512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}